Abstract
Expression of the Bcr-Abl oncoprotein alters various aspects of hematopoietic cells. We investigated the effects of a Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate, on the proliferation, adhesive properties, and morphology of a Bcr-Abl-transferred cell line, TF-1 Bcr-Abl, in comparison with parental TF-1. First, the factor-independent growth of TF-1 Bcr-Abl was inhibited in the presence of imatinib mesylate, but this inhibition was overcome by addition of exogenous granulocyte-macrophage colony-stimulating factor. Imatinib mesylate remarkably reduced tyrosine phosphorylation of Bcr-Abl, Cbl, and Crkl in a time-dependent manner, and their complex formation also was affected. Imatinib mesylate inhibited activation of Stat5 rather than the MEK-ERK1/2 pathway. TF-1 Bcr-Abl cells exhibited a round shape, unlike TF-1, and the adhesive property to fibronectin was much lower than that of TF-1. Although the Bcr-Abl oncoprotein may be involved negatively in cell adhesion, the decreased adhesion and altered morphology of TF-1 Bcr-Abl cells were minimally affected by imatinib mesylate and seemed independent of Bcr-Abl kinase activity. The present data indicated that the Bcr-Abl-specific kinase inhibitor cannot control Bcr-Abl-induced cell alterations other than autonomous growth.Int J Hematol. 2003;78:233-240.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway.EMBO J. 1994;13:764–773.
Mandans RA, Leibowitz DS, Gharehbaghi K, et al. Role of p21 ras in p210 bcr-abl transformation of murine myeloid cells.Blood. 1993;82:1838–1847.
Skorski T, Skorska NS, Szczylik C, et al. c-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hemato- poiesis.Cancer Res. 1995;55:2275–2278.
Iralia RLJ, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.J Biol Chem. 1996;271:31704–31710.
Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ ABL oncogene.Int J Hematol. 2001;73:278–291.
Maru Y. Molecular biology of chronic myeloid leukemia.Int J Hematol. 2001;73:308–322.
Ratiano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.Proc Natl Acad Sci USA. 1995;92:11746–11750.
Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol- 3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.Blood. 1995;86:726–736.
ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.Blood. 1994;84:1731–1736.
Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL- transformed myeloid cells.J Biol Chem. 1997;272:16170–16175.
ten Hoeve J, Kaartinen V, Fioretos T, et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.Cancer Res. 1994;54:2563–2567.
Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD. The BCR/ ABL oncogene alters interaction of the adaptor proteins CRKL and CRK with cellular proteins.Leukemia. 1997;11:376–385.
Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.Cell. 1993;75:175–185.
Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.Oncogene. 1997;15:2333–2342.
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.Blood. 1994;83:2038–2044.
Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia.Nature. 1987;328:342–344.
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome.N Engl J Med. 2001;344:1038–1042.
Tauchi T, Ohyashiki K, Yamashita Y, Sugimoto S, Toyama K. SH2- containing phospho-tyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways.Int J Oncol. 1997;11:471–476.
Thiesing JT, Jones SO, Kolibaba KS, Drucer BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents Bcr-Abl-positive cells.Blood. 2000;96:3195–3199.
Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by chronic myelogenous leukemia-specific p210bcr/abl protein.Proc Natl Acad Sci USA. 1988;85:9312–9316.
Carpino N, Wisniewski D, Strife A, et al. p62DOK: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.Cell. 1997;88:197–204.
Matsuguchi T, Salgia R, Hallek M, et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony- stimulating factor and is constitutively increased by p210BCR/ABL.J Biol Chem. 1994;269:5016–5021.
Salgia R, Li JL, Lo SH, et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.J Biol Chem. 1995;270:5039–5047.
Gotoh A, Miyazawa K, Ohyashiki K, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR- ABL oncoprotein.Exp Hematol. 1995;23:1153–1159.
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated-protein in neutrophils from patients with chronic myelogenous leukemia.J Biol Chem. 1994;269:22925–22928.
Sattler M, Salgia R, Shrikhande G, et al. Steel factor induces tyrosine phosphorylation of Crkl and binding of Crkl to a complex containing c-kit, phosphatidyl-inositol 3-kinase, and p120Cbl.J Biol Chem. 1997;272:10248–10253.
Sattler M, Salgia R, Shrikhande G, et al. Differential signaling after beta-1 integrin ligation is mediated through binding of Crkl to p120CBL and p110HEF1.J Biol Chem. 1997;272:14320–14326.
Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated RAP1.Science. 1997;287:124–128.
Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?J Lab Clin Med. 1997;129:584–591.
Andoniou CE, Thien CB, Langdon WY. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.EMBO J. 1994;13:4515–4523.
Salgia R, Pisick E, Sattler M, et al. p130CAS forms a signaling complex with the adaptor protein CRKL in hematopoietic cells.J Biol Chem. 1996;271:25198–25203.
Heaney C, Kolibaba K, Bhat A, et al. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.Blood. 1997;89:297–306.
de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. CRKL is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.J Biol Chem. 1995;270:21468–21471.
Hurley RW, McCathy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation.J Clin Invest. 1995;96:511–519.
Kramer A, Horner S, Willer A, et al. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.Proc Natl Acad Sci USA. 1999;96:2087–2092.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nishihara, T., Miura, Y., Tohyama, Y. et al. Effects of the Tyrosine Kinase Inhibitor Imatinib Mesylate on a Bcr-Abl-Positive Cell Line: Suppression of Autonomous Cell Growth but No Effect on Decreased Adhesive Property and Morphological Changes. Int J Hematol 78, 233–240 (2003). https://doi.org/10.1007/BF02983800
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983800